Literature DB >> 20495314

Evaluation of QOL for stem cell transplantation recipients by SF-36 and FACT-BMT: preliminary results of FACT-BMT for Japanese patients.

Osamu Imataki1, Kazuko Nakajima, Naomi Inoue, Yotaro Tamai, Kimihiro Kawakami.   

Abstract

BACKGROUND: Quality of life (QOL) measurement is a powerful instrument for assessing medical morbidity from the patient's perspective. We measured the QOL of patients undergoing autologous and allogeneic stem cell transplantation (SCT) in Japan to validate the FACT-BMT scale in comparison to SF-36.
METHODS: We performed a cross-sectional survey for transplant recipients receiving treatment at our outpatient clinic. Recipients undergoing autologous and allogeneic SCT between October 2002 and March 2006 were eligible. Participants completed both the Medical Outcomes Study 36-Item Short Form (SF-36) and a Functional Assessment of Cancer Therapy survey specific to bone marrow transplantation (FACT-BMT).
RESULTS: Thirty-six patients were enlisted, including 24 post-autologous SCT patients and 12 post-allogeneic SCT patients. The median time required to answer all questions was 9 and 11 minutes for SF-36 and FACT-BMT surveys, respectively. Cronbach's a was over 0. 7 for all domains in both SF-36 and FACT-BMT. Inter-scale correlations between all domains except for BP in SF-36 and BMT in FACT-BMT had correlation coefficients greater than 0. 4. The internal consistencies of both surveys were confirmed in Japanese patients.
CONCLUSIONS: Our study indicated the feasibility and partial validity of FACT-BMT in a one-time follow-up of QOL for Japanese patients after SCT.

Entities:  

Mesh:

Year:  2010        PMID: 20495314

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  An urban neo-poverty population-based quality of life and related social characteristics investigation from northeast China.

Authors:  Fengrong Ou; Kai Li; Qian Gao; Dan Liu; Jinghai Li; Liwen Hu; Xian Wu; E Kale Edmiston; Yang Liu
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.